Skip to content

US · SILO · BIOTECHNOLOGY

Silo Pharma, Inc. (SILO) intrinsic value and stock valuation

$1.71as of 2026-11-21 · Mkt cap 4.22M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Silo Pharma, Inc. DCF and intrinsic value

InvestorsCraft values SILO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SILO’s statements →

Silo Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sarasota, FL 34236 silopharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$70K
20112025
Net income
-$-4.23M
20112025
Free cash flow
-$-4.66M
20112025
Total equity
$6.31M+37.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$70K$70K$70K$70K$70K
Operating income-$-4.28M-$-4.71M-$-3.86M-$-3.63M-$-2.74M
Net income-$-4.23M-$-4.39M-$-3.7M-$-3.91M$3.9M
EPSd-$-7.55M-$-17.56M-$-17.62M-$-26.07M$30M
Operating cash flow-$-4.66M-$-3.83M-$-3.22M-$-3.5M-$-2.28M
Capital expenditure$0.00$0.00$0.00$0.00-$0.00
Free cash flow-$-4.66M-$-3.83M-$-3.22M-$-3.5M-$-2.28M
Total assets$7.61M$7.41M$7.75M$11.6M$10.5M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-4.75M-$-3.91M-$-3.52M-$-11.37M-$-9.84M
Total equity$6.31M$5.03M$6.18M$10.3M$9.06M
Cash and short-term investments$6.86M$7.08M$7.67M$11.4M$10.3M
Income statement
20252024202320222021
Revenue$70K$70K$70K$70K$70K
Cost of revenue$890K$10K$10K$10K$10K
Gross profit-$-810K$70K$70K$70K$70K
Research and development expenses$2.16M$2.37M$850K$1.29M$690K
Selling, general and administrative expenses$2.15M$2.4M$3.08M$2.43M$2.27M
Other expenses-$-840K$0.00$0.00-$-20K-$-150K
Operating expenses$3.47M$4.77M$3.92M$3.69M$2.81M
Cost and expenses$4.35M$4.78M$3.93M$3.7M$2.82M
Interest income$190K$330K$400K$70K$0.00
Interest expense$40K$10K$0.00$0.00$0.00
Depreciation and amortization$10K$10K$0.00$0.00$0.00
Ebitda-$-4.18M-$-4.38M-$-3.63M-$-3.91M$4.19M
Operating income-$-4.28M-$-4.71M-$-3.86M-$-3.63M-$-2.74M
Total other income/expenses, net$50K$310K$220K-$-280K$6.93M
Income before tax-$-4.23M-$-4.39M-$-3.63M-$-3.91M$4.18M
Income tax expense$0.00$0.00$0.00$0.00$20K
Net income-$-4.23M-$-4.39M-$-3.7M-$-3.91M$3.9M
Weighted average shares outstanding$560K$250K$210K$150K$130K
Weighted average diluted shares outstanding$560K$250K$210K$150K$130K
Balance sheet
20252024202320222021
Cash and short-term investments$6.86M$7.08M$7.67M$11.4M$10.3M
Net receivables$0.00$0.00$0.00$70K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.39M$7.11M$7.68M$11.6M$10.4M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$220K$240K$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$60K
Total non-current assets$220K$300K$60K$70K$90K
Total assets$7.61M$7.41M$7.75M$11.6M$10.5M
Accounts payable$580K$1.58M$700K$360K$420K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$70K$70K$70K$70K$70K
Total current liabilities$650K$1.66M$780K$440K$490K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$650K$720K$790K$870K$940K
Total non-current liabilities$650K$720K$790K$870K$940K
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.3M$2.38M$1.57M$1.3M$1.43M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-19.49M-$-15.26M-$-10.87M-$-7.17M-$-3.26M
Accumulated other comprehensive income (loss)$10K$0.00-$-10K$0.00$0.00
Total equity$6.31M$5.03M$6.18M$10.3M$9.06M
Total investments$2.11M$3.17M$4.14M$0.00$480K
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-4.75M-$-3.91M-$-3.52M-$-11.37M-$-9.84M
Cash flow statement
20252024202320222021
Net income-$-4.23M-$-4.39M-$-3.7M-$-3.91M$4.16M
Depreciation and amortization$10K$10K$0.00$0.00$0.00
Stock-based compensation$120K$0.00$10K$160K$0.00
Change in working capital-$-1.18M$550K$300K-$-80K$700K
Accounts receivable$0.00$0.00-$0.00-$0.00-$0.00
Inventory$0.00$0.00$0.00$0.00-$-20K
Accounts payable$0.00$0.00$340K-$-50K$0.00
Net cash provided by operating activities-$-4.66M-$-3.83M-$-3.22M-$-3.5M-$-2.28M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$640K$970K-$-4.15M$90K$7.19M
Common stock issued$4.86M$3.41M$0.00$4.94M$3.79M
Common stock repurchased$0.00-$-170K-$-470K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.86M$3.24M-$-470K$4.94M$3.79M
Net change in cash$840K$380K-$-7.84M$1.53M$8.71M
Cash at end of period$4.75M$3.91M$3.52M$11.4M$9.84M
Operating cash flow-$-4.66M-$-3.83M-$-3.22M-$-3.5M-$-2.28M
Capital expenditure$0.00$0.00$0.00$0.00-$0.00
Free cash flow-$-4.66M-$-3.83M-$-3.22M-$-3.5M-$-2.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Silo Pharma, Inc.

        Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.

        CEO
        Eric Weisblum
        Employees
        3
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Silo Pharma, Inc. (SILO)?

        InvestorsCraft does not currently publish an intrinsic value for SILO. How the IC value is calculated.

        Is SILO undervalued?

        InvestorsCraft does not publish an undervaluation signal for SILO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.